VBI Vaccines (VBIV) Hits New 1-Year Low at $1.64

VBI Vaccines Inc (NASDAQ:VBIV) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $1.64 and last traded at $1.69, with a volume of 2171 shares traded. The stock had previously closed at $1.72.

Several brokerages have recently commented on VBIV. Zacks Investment Research downgraded VBI Vaccines from a “hold” rating to a “sell” rating in a report on Friday, September 28th. BMO Capital Markets reduced their target price on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, July 27th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. VBI Vaccines currently has a consensus rating of “Hold” and an average target price of $9.08.

The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 0.14.

In other VBI Vaccines news, CEO Jeff Baxter bought 13,500 shares of VBI Vaccines stock in a transaction dated Friday, August 3rd. The shares were acquired at an average cost of $2.01 per share, with a total value of $27,135.00. Following the acquisition, the chief executive officer now directly owns 224,905 shares of the company’s stock, valued at $452,059.05. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 23,600 shares of company stock worth $46,788 over the last three months. 16.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Menora Mivtachim Holdings LTD. boosted its holdings in shares of VBI Vaccines by 27.4% in the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 3,459,868 shares of the biopharmaceutical company’s stock worth $9,515,000 after acquiring an additional 744,706 shares in the last quarter. Altshuler Shaham Ltd raised its position in VBI Vaccines by 11.5% in the 2nd quarter. Altshuler Shaham Ltd now owns 891,442 shares of the biopharmaceutical company’s stock worth $2,452,000 after purchasing an additional 91,800 shares during the last quarter. General American Investors Co. Inc. raised its position in VBI Vaccines by 44.1% in the 2nd quarter. General American Investors Co. Inc. now owns 864,464 shares of the biopharmaceutical company’s stock worth $2,377,000 after purchasing an additional 264,464 shares during the last quarter. Millennium Management LLC raised its position in VBI Vaccines by 118.7% in the 2nd quarter. Millennium Management LLC now owns 531,117 shares of the biopharmaceutical company’s stock worth $1,461,000 after purchasing an additional 288,214 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in VBI Vaccines by 7.3% in the 1st quarter. Russell Investments Group Ltd. now owns 491,449 shares of the biopharmaceutical company’s stock worth $1,720,000 after purchasing an additional 33,588 shares during the last quarter. 48.00% of the stock is currently owned by institutional investors and hedge funds.

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Recommended Story: Growth Stocks

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply